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Abstract
Male development, fertility, and lifelong health are all androgen-dependent. 
Approximately 95% of circulating testosterone is synthesized by the testis and the 
final step in this canonical pathway is controlled by the activity of the hydroxys-
teroid-dehydrogenase-17-beta-3 (HSD17B3). To determine the role of HSD17B3 
in testosterone production and androgenization during male development and func-
tion we have characterized a mouse model lacking HSD17B3. The data reveal that 
developmental masculinization and fertility are normal in mutant males. Ablation 
of HSD17B3 inhibits hyperstimulation of testosterone production by hCG, al-
though basal testosterone levels are maintained despite the absence of HSD17B3. 
Reintroduction of HSD17B3 via gene-delivery to Sertoli cells in adulthood partially 
rescues the adult phenotype, showing that, as in development, different cell-types 
in the testis are able to work together to produce testosterone. Together, these data 
show that HS17B3 acts as a rate-limiting-step for the maximum level of testos-
terone production by the testis but does not control basal testosterone production. 
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1 |  INTRODUCTION
Male development, fertility, and lifelong health and wellbe-
ing are all androgen-dependent. Perturbed androgen action at 
any stage of life, but particularly during aging,1 significantly 
impacts the quality of life, and low androgens are an inde-
pendent risk factor for all-cause early death.2 The long-es-
tablished paradigm of androgen action identifies testosterone 
(T) as the key androgen driving male development and func-
tion. The final step in this canonical pathway is controlled 
by the essential activity of a single testis-specific 17-ketos-
teroid reductase enzyme, hydroxysteroid dehydrogenase 17-
beta 3 (HSD17B3). During development in mice, HSD17B3 
is expressed in testicular Sertoli cells where it functions to 
produce testosterone from androstenedione derived from the 
fetal Leydig cells. Expression of HSD17B3 switches from 
Sertoli cells in fetal life to the adult Leydig cell population in 
prepubertal life that produces testosterone directly.3,4
The importance of HSD17B3 for testicular testosterone 
production in humans is highlighted in differences/disorders of 
sex development involving mutations in HSD17B3 that reduce 
its function. Individuals with perturbed HSD17B3 function are 
under-masculinized at birth, with hypoplastic to normal inter-
nal genitalia (epididymis, vas deferens, seminal vesicles, and 
ejaculatory ducts), but with female external genitalia and the 
absence of a prostate.5-7 Inadequate testosterone production 
by the testis reduces the availability of dihydrotestosterone in 
peripheral tissues leading to under-masculinization of the ex-
ternal genitalia during development. During puberty, increased 
luteinizing hormone (LH) stimulation of testicular androgen 
production leads to an increase in production and secretion of 
androstenedione (the precursor of testosterone). A diagnostic 
marker of HSD17B3 deficiency is, therefore, a high andro-
stenedione to testosterone ratio in the blood.8 Conversion of an-
drostenedione to testosterone/dihydrotestosterone in peripheral 
tissues promotes masculinization at puberty, failure of which is 
another diagnostic marker of HSD17B3 deficiency.
The presence or absence of male internal reproductive 
organs and external genitalia is critically dependent upon 
signaling via the androgen receptor (AR) during the mas-
culinization programming window in fetal life.9 Stimulation 
of AR with androgens prior to this window does neither in-
duce premature masculinization,10 nor can stimulation with 
androgens after this window has closed, drive the establish-
ment of male internal genitalia if AR is blocked during the 
window.9 During the programming window, testicular tes-
tosterone is the androgen that drives internal masculinization 
and it is curious, therefore, that some individuals lacking 
HSD17B3 show signs of internal masculinization during 
fetal life.11 This may reflect the nature of the specific mu-
tations that reduce, but do not completely ablate, testoster-
one production in the testis. Alternatively, it may suggest the 
presence of another mechanism driving testosterone produc-
tion that does not require the function of HSD17B3.
To address this, we have characterized a mouse model 
in which HSD17B3 has been completely ablated (complete 
knockout model). Consistent with the range of diagnoses in 
humans lacking HSD17B3, knockout mice develop normal 
internal genitalia at birth. In adulthood, as with humans lack-
ing HSD17B3, knockout mice also display a high androstene-
dione to testosterone ratio. Surprisingly, however, HSD17B3 
knockout mice continue to produce testosterone, display 
normal spermatogenesis and are fertile, something that is 
widely accepted to be fundamentally dependent upon the 
17-ketosteroid reductase activity of HSD17B3 and its ability 
to produce testosterone. Together, these data identify an as 
yet uncharacterized, alternative mechanism driving testoster-
one production in the testis that functions independently of 
HSD17B3, which has implications for our understanding of 
testosterone production in males.
2 |  MATERIALS AND METHODS
2.1 | Breeding of transgenic mice
The knockout model Hsd17b3tm(lacZ;neo)lex was provided by 
Lexicon, Taconic, and generated using classical gene target-
ing approaches. A selection cassette was inserted into exon 
1 (chromosome 13) to generate a subsequent frameshift 
mutation and was undertaken on genetic background 129/
svEv-C57bl/6. Heterozygous Hsd17b3tm(lacZ;neo)lex; +/− (re-
ferred as Hsd17b3+/−) males and females were bred together 
to generate Hsd17b3+/+, Hsd17b3+/−, and Hsd17b3−/− ani-
mals. Animals were identified by genotyping from ear or 
tail DNA for the presence of Hsd17b3 and the presence of 
Measurement of other enzymes able to convert androstenedione to testosterone iden-
tifies HSD17B12 as a candidate enzyme capable of driving basal testosterone produc-
tion in the testis. Together, these findings expand our understanding of testosterone 
production in males.
K E Y W O R D S
androgens, HSD17B3, HSD17B12, Leydig cell, testis, testosterone
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mutated allele (Neo) using standard PCR with appropriate 
primers (Table 1). Mice were housed under standard condi-
tions of care and bred as described in the results. Experiments 
passed local ethical review and were conducted with licensed 
permission under the UK Animal Scientific Procedures Act 
(1986), Home Office license number PPL 70/8804 and in 
accordance with the University of Newcastle's Animal Care 
Ethics Committee guidelines (Approval No. A-2018-820).
2.2 | Trophic stimulation
To examine the testicular response to acute trophic stimu-
lation in vivo, adult animals were given a single IP injec-
tion of 20IU human chorionic gonadotrophin hCG (Pregnyl, 
Organon), and then, sacrificed 16 hours later. Serum was col-
lected for measurement of testosterone levels.
2.3 | Lentiviral production
Lentiviral particles contained CMV-mouse Hsd17b3 and 
GFP (emGFP) transgenes separated with an IRES site or 
CMV-emGFP alone. Shuttle vectors were packaged with a 
third generation Lentiviral vector plasmid pseudotyped for 
VSV-G, concentrated to a viral titer of > 5 × 109 TU/mL in 
serum free media.12
2.4 | Lentiviral injection
Procedures were performed under anesthesia by inhalation of 
isoflurane and under aseptic conditions. In brief, the lower abdo-
men was shaved and sterilized before a small incision was made 
in the abdominal muscle wall. Testes were exposed through the 
incision and, under a dissection microscope, the efferent duct 
and areas around the rete testis were isolated from surround-
ing adipose tissue taking care not to rupture blood vessels and 
to keep the testes moist at all times with sterile saline. Up to 
10 µL of the lentiviral particle suspension were introduced into 
the seminiferous tubules of adult (day 120) Hsd17b3−/− males 
and control littermates via the rete testis (similar to techniques 
reported by Ref. [13]) using a glass micropipette (outer diam-
eter: 80 µm, beveled) (Biomedical Instruments, Germany) and 
a microinjector (Eppendorf Femtojet; Eppendorf, Germany) at 
a pressure of 25 hPA. Delivery of particles was monitored by 
the addition of Trypan Blue dye to the viral particles (0.04%). 
Testes were then carefully replaced back into the abdominal 
cavity, taking care to ensure access to the scrotal compartment 
was present, and incisions were closed using sterile sutures. 
Mice were injected subcutaneously with 0.05 mg/kg buprenor-
phine (Vetergesic; Ceva Animal Health Ltd, UK) while an-
esthetized and allowed to recover on a heat pad while being 
monitored. Animals were culled (as described below) and testis 
recovered 7 weeks postsurgery and imaged in cold phosphate-
buffered saline with a Leica MZFLIII microscope (Wetzlar, 
Germany) and an epifluorescent green fluorescent protein 
(GFP) filter. Testes were weighed and fixed separately in 
Bouins fixative (Clin-Tech Ltd, UK) for 6 hours before being 
transferred to 70% of ethanol prior to processing into paraffin 
wax and sectioned at 5 µm for histological analysis.
2.5 | Tissue collection
Animals were culled at different key points of testis devel-
opment by CO2 inhalation and subsequent cervical disloca-
tion. Blood was obtained by cardiac puncture for hormonal 
profile analysis. Plasma was separated by centrifugation and 
stored at −80°C. Bodyweight and reproductive organ (testis 
and seminal vesicle) weights were recorded. Collected tis-
sues were either fixed or frozen for RNA or protein analysis.
T A B L E  1  Primer list
Gene Forward primer Reverse primer Probe
Hsd17b3 (WT) gatgcctgcgaatcacaag ccattgatcgcaggaaagag genomic
Hsd17b3 (mutant neomycin) gcagcgcatcgccttctatc gtgaatagaggcacagaatgc genomic
Lhcgr gatgcacagtggcaccttc cctgcaatttggtggaagag UPL #107
Star aaactcacttggctgctcagta tgcgataggacctggttgat UPL #83
Cyp11a1 aagtatggccccatttacagg tggggtccacgatgtaaact UPL #104
Hsd3b1 gaactgcaggaggtcagagc gcactgggcatccagaat UPL #12
Cyp17a1 catcccacacaaggctaaca cagtgcccagagattgatga UPL #67
Hsd17b3 atgggcagtgattaccggagca tacaatcttcacacagcttccagtggtc UPL #47
Hsd17b1 ccccacggtagtgctcatt ccgcaatgtggcataaact UPL #82
Hsd17b5 ccattggggtgtccaactt ccagaagttttccctgattga UPL #27
Hsd17b12 cgtggaatgaagattgtcctg cagcaatggtccttgtttca UPL #62
Luciferase gcacatatcgaggtgaacatcac gccaaccgaacggacattt 5’NED-tacgcggaatacttc
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2.6 | Quantitative RT-PCR
Quantitative RT-PCR was performed as previously described14 
with minor modifications. RNA concentration was estimated 
using a NanoDrop One spectrophotometer (Thermo Fisher 
Scientific) and cDNA was prepared using the SuperScript 
VILO cDNA synthesis Kit (Invitrogen). cDNA quality was 
assessed using Universal ProbeLibrary Mouse ACTB Gene 
Assay (Sigma). Real-time PCR was carried out on the ABI 
Prism 7900HT Real-Time PCR System (Applied Biosystems) 
in 384-well format using TaqMan Universal PCR Master 
Mix (Applied Biosystems) and the Universal Probe Library 
(Roche).14 Details of each assay are listed in Table 1.
2.7 | Immunostaining
Tissues were fixed in Bouins for 6  hours, stored in 70% 
of ethanol, and embedded in paraffin or in resin (see 
below). Sections were processed as previously described.15 
Succinctly slides were dewaxed and rehydrated prior antigen 
retrieval in 0.01 M citrate buffer (pH 6.0). Successive steps to 
reduce the endogenous peroxidases activity and to block the 
nonspecific activity were undertaken and followed by incu-
bation overnight at 4°C with the primary antibodies Table 2. 
After washing, slides were incubated for 30 minutes at room 
temperature with the appropriate secondary antibody conju-
gated to peroxidase. Sections were incubated with fluores-
cein Tyramide Signal Amplification system (“TSA”, Perkin 
Elmer) according to manufacturer's instructions. Sections 
were counterstained in Sytox Green (Molecular Probes, 
life technologies, Paisley, UK) and mounted in PermaFluor 
mounting medium (Thermo Scientific, UK). Slides were im-
aged using a LSM 710 confocal microscope and ZEN 2009 
software (Carl Zeiss Ltd, Hertfordshire, UK). Control sec-
tions were incubated with no primary antibody. At least three 
different animals from each group were tested and processed 
simultaneously.
2.8 | Stereology and histology
For stereology, testes were embedded in Technovit 7100 
resin, cut into 20  µm sections, and stained with Harris’ 
T A B L E  2  Details of antibodies and detection methods used
Primary 
antibody 
(AbI) name References
Dilution 
AbI RRID
Secondary antibody 
(AbII) conjugated
Dilution 
AbII
Detection 
system
HSD17B3 Santa Cruz 
sc-135044
1/2000 AB_10658251 Peroxidase Vector 
Laboratories 
PI-1000
1/200 IF
SOX9 Millipore Ab5535 1/8000 AB_2239761 Peroxidase Vector 
Laboratories 
PI-1000
1/200 IF
3 β-HSD Santa Cruz 
Biotechnology 
sc-30820
1/750 AB_2279878 Peroxidase Santa Cruz 
Biotechnology 
sc-2961
1/200 IF
CYP17A1 Santa Cruz 
Biotechnology 
sc-46081
1/1000 AB_2088659 Peroxidase Santa Cruz 
Biotechnology 
sc-2961
1/200 IF
DDX4 Abcam Ltd. 
Ab13840
1/400 AB_443012 Peroxidase Vector 
Laboratories 
PI-1000
1/200 IF
CL.CASPASE 
3
Cell signalling 
(NEB) #9661
1/500 AB_2341188 Peroxidase Vector 
Laboratories 
PI-1000
1/200 IF
Green 
Fluorescent 
Protein 
(enhanced) 
(eGFP)
Abcam ab6556 1/200 AB_305564 Peroxidase Vector 
Laboratories 
PI-1000
1/200 IF
HSD17B12 LSBio LS-B16612 1/100 Not classified ImmPRESS HRP Goat 
Anti-Rabbit IgG Polymer 
Detection Ki
Vector 
Laboratories 
MP-7451
IHC
Abbreviations: IF, immunofluorescence; IHC, immunohistochemistry.
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hematoxylin, as previously described in Ref. [15]. The num-
ber of Leydig cells and Sertoli cells was determined by the 
optical disector method using an Olympus BX50 microscope 
fitted with a motorized stage (Prior Scientific Instruments, 
Cambridge, UK) and Stereologer software (Systems Planning 
Analysis, Alexandria, VA).
2.9 | Intratesticular steroid extraction
A fragment of frozen testis was weight and homogenized in 
lysis buffer (50 mM Tris pH 7.4, 1% of deoxycholate, 0.1% 
of SDS). Steroids were extracted from testis lysate or from 
plasma using diethyl ether, dried under a constant stream of 
nitrogen, and then, resuspended in the appropriate buffer for 
analysis.
2.10 | Hormone analysis
Concentrations of the gonadotropins luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH) were assessed 
using the Milliplex Map Pituitary Magnetic Bead Panel Kit 
(PPTMAG-86K; MilliporeSigma, Burlington, MA, USA) 
inter-assay cv  <20%, intra-assay cv  <15%, range 24.4-
100 000 pg/mL for FSH and 4.9-20 000 pg/mL for LH ac-
cording to the manufacturer's instructions. A Bio-Plex 200 
suspension array system was used to measure plasma con-
centrations and data were analyzed with Bio-Plex Manager 
software (Bio-Rad Laboratories, Hercules, CA, USA). Our 
experimental intra CV for FSH assay  <6.5 and for LH 
assay <3.4.
The steroids in mouse plasma and testis lysate were mea-
sured using an isotope-dilution TurboFlow liquid chroma-
tography-tandem mass spectrometry method as previously 
described.14,16 For progesterone, 17-OH-progesterone (17-
OHP), androstenedione, and testosterone the limits of quan-
tification were 0.036 nM, 0.1 pM, 0.012 nM, and 0.042 nM, 
respectively, and the interday variation, expressed as the 
relative standard deviation for these analytes were testoster-
one was ≤5.3% and ≤4.2% for low and high spike levels of 
control materials, respectively, included three times each in 
every analytical batch. Chemical analyses were performed 
at the Dept. of Growth and Reproduction, Rigshospitalet, 
Copenhagen University Hospital.
2.11 | Image analysis
Histological slides were analyzed and photographed using 
a Provis microscope (Olympus Optical, London, UK) fitted 
with a DCS330 digital camera (Eastman Kodak, Rochester, 
NY). For immunofluorescence, slides were imaged using a 
LSM 710 confocal microscope and ZEN 2009 software (Carl 
Zeiss Ltd, Hertfordshire, UK). Images were compiled using 
Adobe Photoshop CS6 and Adobe Illustrator 2019 (Adobe 
System Inc, Mountain View, CA, USA).
2.12 | Statistical analysis
Data were analyzed using Graph Prism version 8 (GraphPad 
Software Inc, San Diego, CA, USA). Statistical analyses in-
volved Student t test or one- or two-way ANOVA with the 
appropriate post hoc tests (Tukey's multiple comparisons or 
Dunnett's tests). When required, data were normalized using 
log transformation. Values are expressed as means ± SEM 
*P < .05, **P < .01, ***P < .001, ****P < .0001.
3 |  RESULTS
3.1 | HSD17B3 is localized to Sertoli cells in 
fetal life and Leydig cells in adulthood
Expression of HSD17B3 has been reported to occur in dif-
ferent cell-types depending on the stage of development 
of the testis.3,17 Using immunofluorescence to localize 
HSD17B3 in fetal and adult testes, we confirmed that ex-
pression of this enzyme is restricted to Sertoli cells at e16.5, 
(Figure  1A) (and this was further verified using a mouse 
model that lacks Sertoli cells, Figure 1A insert)15 while, in 
adulthood, the expression is restricted to the Leydig cells 
(Figure 1A). Taken together the data confirm the previously 
published data describing the spatiotemporal expression 
profile of HSD17B3.3,17
3.2 | Disruption of exon 1 of Hsd17b3 
produces a HSD17B3 loss of function model
To understand the importance of HSD17B3 function in male 
development and fertility, we characterized a transgenic 
mouse model, in which exon 1 of the Hsd17b3 gene had been 
disrupted via insertion of a LacZ/Neo expression cassette 
(Figure 1B,C). Interrogation of testicular cDNA by q-RTPCR 
confirmed the absence of Hsd17b3 transcripts in Hsd17b3−/− 
mice (Figure 1D) and lack of detectable HSD17B3 protein 
in the testis (Figure 1E). As with cases of HSD17B3 defi-
ciency in humans, there was a marked increase in the andros-
tenedione to testosterone (D4/T) ratio in Hsd17b3−/− mice 
under both basal and hyper-stimulation (+hCG) conditions 
(Figure 1F). Together these data confirm the successful pro-
duction of a mouse model lacking HSD17B3.
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3.3 | Blocking of the canonical 
testosterone production pathway 
via ablation of HSD17B3 function 
does not impact the development of the internal 
male genitalia
To assess the impact on male development following the abla-
tion of HSD17B3 function, we first analyzed the gross mor-
phology of the genitalia and wider reproductive system in both 
neonatal (postnatal day 0: d0) and adult (d80) Hsd17b3−/− ani-
mals. At birth, anogenital distance (AGD, a biomarker of andro-
gen action during the masculinization programming window9 
was normal in Hsd17b3−/− males (Figure 2A). Consistent with 
this, other androgen-dependent endpoints also developed nor-
mally: the initial segment of the epididymis was present18 and 
Wolffian duct/epididymis coiled normally19 in Hsd17b3+/− and 
Hsd17b3−/− animals (Figure  2B). In adulthood, there was 
no difference in body weight between the genotypes at d80 
(Figure 2C) and the gross reproductive system of Hsd17b3−/− 
males appeared unchanged with respect to control animals 
(Figure 2D). Importantly, two key biomarkers of androgen ac-
tion, testis weight (a biomarker of internal testicular androgens) 
(Figure 2E) and seminal vesicle weight (a biomarker of circu-
lating androgens) (Figure 2 F) did not differ from wild-type 
or heterozygous controls, suggesting that androgen signaling is 
not impacted at d80. However, a small reduction in AGD was 
observed in d80 Hsd17b3−/− males (Figure 2G), suggestive of 
a mild perturbation to androgen signaling in adulthood.20 As 
no difference was observed in any endpoint between wild-type 
and heterozygous these groups were combined for downstream 
analyses and termed ‘controls’.
3.4 | Blocking of the canonical testosterone 
production pathway does not alter 
male fertility
To determine the impact of the loss of HSD17B3 function on 
the adult testis, we first assessed the histology and cell compo-
sition of the testis. We undertook hematoxylin-eosin staining 
and immunofluorescence localization using specific Sertoli 
cell (SOX9), germ cells (DDX4), and Leydig cell (HSD3B 
and CYP17A1) markers at d0 and in adulthood. At both time-
points the testicular histology, cell localization, and composi-
tion of different cell types (including all stages of germ cell 
development) were normal in Hsd17b3−/− animals (Figure 3A-
D and supplemental Figure S1). Similarly, numbers of Sertoli 
cells and Leydig cells in adulthood did not differ between 
control and Hsd17b3−/− males (Figure 3E-F). As the overall 
composition of the testis in Hsd17b3−/− males was normal, 
we next assessed whether these males, lacking HSD17B3 
function, were fertile. Upon analysis, the cauda epididymes 
F I G U R E  1  Validation of the HSD17B3 loss of function model. A, The spatiotemporal expression of HSD17B3 in wild-type fetal mouse testis 
(e16.5) shows expression is restricted to Sertoli cells at e16.5 (inset shows absence of staining in e16.5 fetal testis using a mouse model depleted 
of Sertoli cells). In the wild-type adult testis, HSD17B3 localizes to the Leydig cells (insert shows negative control) (bar: 100 µm). B, Schematic 
model of the knock-in in Hsd17b3 exon 1, detailing the localization of the primers on WT and mutant alleles. C, PCR analysis of the genomic 
DNA isolated from ear clips for Hsd17b3+/+ (317 bp), Hsd17b3+/− (317 bp and 522 bp), and Hsd17b3−/− (522 bp) alleles. D, Relative expression of 
Hsd17b3 transcripts, normalized to exogenous luciferase, shows a significant reduction in the expression of Hsd17b3 in Hsd17b3−/− testes (n = 6 
Hsd17b3+/+, n = 7 Hsd17b3+/−, n = 8 Hsd17b3−/−, ANOVA, ****P < .0001). E, Immunolocalization of HSD17B3 in adult testis shows an absence 
of staining in Hsd17b3−/− compared to Hsd17b3+/+ and Hsd17b3+/− mice (scale bar: 100 µm). F, Ratio of circulating levels of androstenedione 
(D4) to testosterone (T) at d80 under both basal and hyper-stimulated (+hCG) conditions (n = 11(basal) n = 3 (+hCG) Hsd17b3+/+, n = 13 (basal) 
n = 8 (+hCG) Hsd17b3+/−, n = 12 (basal) n = 6 (+hCG) Hsd17b3−/−, ANOVA ****P < .0001)
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in Hsd17b3−/− animals were found to contain abundant sper-
matozoa (Figure 3G) and when Hsd17b3−/− males were bred, 
viable pregnancies resulted, with no significant difference in 
the number of pups born compared to matings using wild-type 
littermate controls as studs (Figure 3H). These data show that 
overall testicular development and fertility are not altered fol-
lowing the loss of HSD17B3.
3.5 | Blocking of the canonical testosterone  
production pathway promotes a functional  
response within Leydig cells to maintain  
normal basal testosterone concentrations
To understand how male mice lacking HSD17B3 appar-
ently exhibit a near-normal phenotype, we next analyzed 
the impact of ablation of HSD17B3 on Leydig cell func-
tion. Assessment of Leydig cell function in adult (d80) 
mice lacking HSD17B3 revealed a significant upregula-
tion of Lhcgr transcripts in addition to transcripts encod-
ing most of the steroidogenic enzymes that function in the 
canonical testosterone production pathway StAR, Cyp11a1, 
and Cyp17a1 (Figure 4A). Lhcgr, StAR, and Cyp11a1 are 
known to increase expression in response to increased LH 
stimulation,21 suggesting that there is significant hyper-
stimulation of the Leydig cell population in the Hsd17b3−/− 
animals. Measurement of the circulating hormone profile 
in these animals confirmed this, with circulating LH signif-
icantly increased in Hsd17b3−/− males compared to wild-
type males (Figure 4B).
Increased circulating LH is an indicator of possible com-
pensated Leydig cell failure.22 To assess the impact of loss 
F I G U R E  2  HSD17B3 loss of function does not impact the development of internal male genitalia. A, The anogenital distance in neonatal (d0) 
males did not change following HSD17B3 loss of function (n = 8 Hsd17b3+/+, n = 26 Hsd17b3+/−, n = 15 Hsd17b3−/−, ANOVA). B, The gross 
morphology of the genitalia in neonatal (d0) Hsd17b3−/− animals showed normal epididymal coiling. C, Bodyweight in adult (d80) did not differ 
between genotypes (n = 11 Hsd17b3+/+, n = 14 Hsd17b3+/−, n = 13 Hsd17b3−/−, ANOVA). D, The gross morphology of the reproductive system in 
adult (d80) Hsd17b3−/− animals was comparable to controls littermates. Testis (E) and seminal vesicles (F) weights were unchanged in Hsd17b3−/− 
animals at d80 (n = 11 Hsd17b3+/+, n = 14 Hsd17b3+/−, n = 13 Hsd17b3−/−, ANOVA). G, Anogenital distance in adult (d80) males was significantly 
reduced following HSD17B3 loss of function (n = 11 Hsd17b3+/+, n = 14 Hsd17b3+/−, n = 13 Hsd17b3−/−, ANOVA *P < .05, **P < .01)
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of HSD17B3 on Leydig cell function, we measured circu-
lating concentrations of testicular steroids under basal or 
hyper-stimulated conditions (+hCG) in adulthood (d80). 
Circulating progesterone concentrations did not differ be-
tween genotypes under basal or hyper-stimulation condi-
tions (Figure 4C), however, circulating 17-OH-progesterone 
(17-OHP), androstenedione, and surprisingly, circulating 
testosterone, were all significantly higher in the Hsd17b3−/− 
males under basal conditions (Figure  4D-F). 17-OHP and 
testosterone failed to increase further upon hyperstimulation 
in Hsd17b3−/− males in contrast to controls, which showed 
increased levels. These data suggest that in the absence of 
HSD17B3, hCG-mediated hyperstimulation is unable to in-
crease testosterone production.
To investigate this further, we next determined the in-
tratesticular concentrations of the same hormones. This 
revealed that, under basal conditions, progesterone, 17-
OHP, and androstenedione are all significantly increased 
in the testis of Hsd17b3−/− males (Figure  4G-I), while 
testosterone is present in the same concentration as control 
littermates (Figure 4J).
Together these data suggest that HSD17B3 may act as a 
rate-limiting step on testosterone production in response to 
hyperstimulation and, in its absence, the hypothalamus-pi-
tuitary-gonadal (hpg) axis responds in a manner consistent 
with compensated Leydig cell failure to maintain basal 
testosterone production via another pathway resulting in 
increased circulating LH levels in the presence of normal 
testosterone.
3.6 | HSD17B3 acts as a rate-limiting step in 
testicular testosterone production
To address this hypothesis, we sought to rescue the steroido-
genic phenotype of the Hsd17b3−/− adult males by delivery of 
Hsd17b3 cDNA to the testis via lentiviral-mediated gene ther-
apy. We first injected lentivirus into the interstitium resulting 
F I G U R E  3  HSD17B3 loss of function does not alter male fertility. A, Testicular histology was normal in Hsd17b3−/− compared to 
Hsd17b3+/+ animals (bar: 100 µm). Cell composition of the testis using immunofluorescence staining specific for (B) Sertoli cells and germ cells 
(SOX9 and DDX4, respectively) and (C) Leydig cells (HSD3B and CYP17A1) were normal in Hsd17b3−/− males (bar in B-D: 100 µm). E, Sertoli 
and (F) Leydig cell numbers were unchanged in Hsd17b3−/− compared to Hsd17b3+/+ animals (n = 5 Hsd17b3+/+ and n = 4 Hsd17b3−/−, t-test). 
G, The cauda epididymis in Hsd17b3−/− animals contains spermatozoa (bar: 100 µm) and (H) Hsd17b3−/− males are fertile and produce normal 
numbers of pups per litter (n = 4-5 per genotype, t-test)
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in the transduction of Leydig cells, but this also led to Leydig 
cell death within ten days (Figure S2), so we chose to instead 
deliver the lentivirus to adult Sertoli cells (rather than Leydig 
cells) in wild-type and Hsd17b3−/− males using intra-rete in-
jection.12 In retrospect, this provided additional information 
because we were now able to determine (i) whether we could 
rescue the phenotype observed in Hsd17b3−/− males and (ii) 
whether the testis could be induced to function as a single 
testosterone-producing unit in adulthood, analogous to the 
situation in the normal fetal testis.3,4
To validate HSD17B3 transgene delivery and expression, 
cDNA constructs (GFP control, or Hsd17b3) enclosed in len-
tiviral particles were delivered via the rete testis at d120 and 
the testes recovered 7 weeks later (to permit recovery from 
surgery and completion of an entire cycle of spermatogene-
sis). Transgenic expression of HSD17B3 within Sertoli cells 
was confirmed by immunofluorescence (Figure  5A). We 
then repeated the study and processed the tissue to measure 
intratesticular steroid hormone concentrations, to determine 
the impact of restoring HSD17B3 function. Delivery of GFP 
lentivirus (lv GFP) did not modify the intratesticular levels 
of steroids away from those previously observed in untreated 
animals (as in Figure 4H-K). However, in Hsd17b3−/− males 
treated with Hsd17b3 cDNA (lv Hsd17b3), while testicular 
concentrations of progesterone remained unchanged, levels 
of 17-OHP, and androstenedione were both reduced to levels 
observed in control littermates (Figure 5A-B). Testosterone 
concentrations within the testis remained unchanged 
F I G U R E  4  HSD17B3 loss of function impacts Leydig cell but not the intratesticular basal testosterone concentrations. Comparative 
testicular expression of Leydig cell (A) steroidogenic transcripts in adults (d80) (n = 14 controls and n = 8 Hsd17b3−/−, T test ***P < .001, 
****P < .0001). Circulating LH (B) was measured in controls vs Hsd17b3−/− and circulating (C) progesterone, (D) 17-OH-progesterone (17-OHP) 
(E) androstenedione and (F) testosterone were measured in basal and hCG-stimulated conditions in adult (d80) Hsd17b3−/− and controls littermates 
animals (n = 24 (basal) n = 11 (+hCG) and n = 12 (basal) n = 6 (+hCG) Hsd17b3−/−, two-way ANOVA, *P < .05, ***P < .001, ****P < .0001). 
Intratesticular hormones (G) progesterone, (H) 17-OH-progesterone (I) androstenedione and (J) testosterone in adult (d80) Hsd17b3−/− and control 
littermate animals (n = 10 controls and n = 11 Hsd17b3−/−, T test and Mann Whitney, ****P < .0001) under basal conditions. Controls correspond 
to Hsd17b3+/+ males pooled with Hsd17b3+/− males
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(two-way ANOVA P value = .5648) (Figure 5A,B), however, 
circulating LH concentrations also fell to levels consistent 
with control littermates (two-way ANOVA P value = .0010) 
(Figure 5B,C). Together these data show that restoration of 
HSD17B3 function is able to rescue the steroidogenic phe-
notype observed in HSD17B3−/− animals and, also, that this 
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can be achieved via gene delivery to the Sertoli cells, indicat-
ing that the testis can be manipulated to function as a single 
steroidogenic unit in adulthood. This also confirms that the 
role of HSD17B3 is to act as a rate-limiting step in the tes-
tosterone production system in the testis and cannot be fully 
compensated for in this role by another enzyme. However, 
the mechanism underpinning basal testosterone production in 
the absence of HSD17B3 remains unknown.
3.7 | Identification of AKR enzymes 
underpinning basal testosterone production
The production of testosterone in the absence of HSD17B3 
suggests the presence of another aldo-keto reductase enzyme 
(AKR) that performs this role in the testis. The other known 
HSD17Bs capable of converting androstenedione into testos-
terone are HSD17B1, HSD17B5,4,17,23,24 and HSD17B12.25 
When measured by qPCR (Figure S3, Hsd17b1 and Hsd17b5 
transcript levels were below the detection threshold in the 
testis of control and Hsd17b3−/− animals in adulthood. This 
is consistent with previous proteomic analysis of the adult 
mouse testis where both HSD17B1 and HSD17B5 are not de-
tected.26 In contrast, Hsd17b12 transcript levels were quanti-
fiable and show a small but significant increase in expression 
following ablation of HSD17B3 (Figure  6A); HSD17B12 
has previously been identified as a testis-expressed protein in 
both mouse and human26 and immunohistochemistry local-
izes HSD17B12 to Leydig cells and more weakly in the germ 
cells in both control and Hsd17b3−/− testes Figure  6B. As 
the only known AKR enzyme expressed in the mouse testis 
that is able to produce testosterone, other than HSD17B3, the 
significance of HSD17B12 for basal testosterone production 
in the testis requires further investigation.
4 |  DISCUSSION
To determine the role of the steroidogenic enzyme HSD17B3 
in testosterone production and androgenization during male 
development and function, we characterized a mouse model 
lacking HSD17B3. These data reveal that developmental 
masculinization and fertility are normal in male mice lack-
ing the enzyme widely accepted to be critical for the canoni-
cal testosterone production pathway. Ablation of Hsd17b3 
induces compensation of steroidogenic function within the 
testis to maintain normal testosterone levels. Reintroduction 
of Hsd17b3 via gene-delivery to Sertoli cells in adulthood 
rescues this compensation, showing that, as in development, 
different cell-types in the testis can work together to pro-
duce testosterone. The data also confirm that HS17B3 acts 
as a rate-limiting step in testosterone production but does not 
control basal testosterone production. Interrogation of other 
known aldo-keto reductase (AKR) and short-chain dehydro-
genase/reductase enzymes (SDR) enzymes able to produce 
testosterone as a product suggest HSD17B12 as a candidate 
enzyme driving basal testosterone production in the testis in 
the absence of HSD17B3. The data show that testicular an-
drogen production is a well-protected process given its im-
portance in masculinization and male fertility.
Testosterone is essential for masculinization of the male 
fetus,27,28 and HSD17B3 is well established as the critical 
enzyme controlling the conversion of androstenedione to 
testosterone in the canonical testosterone production path-
way in adulthood. Previous studies in mice3,4 have shown 
that, during fetal life, androstenedione produced by fetal 
Leydig cells is converted to testosterone by Sertoli cells. 
Consistent with this, HSD17B3 is expressed in Sertoli cells 
during fetal life and likely acts in this role. However, our 
data reveal that HSD17B3 is, in fact, dispensable for basal 
testosterone production in fetal life, as Hsd17b3−/− mice 
are normally masculinized at birth. This is in contrast to 
humans lacking HSD17B3 function who are under-viril-
ized at birth.11 The explanation for this is unclear, but it 
does suggest the presence of another HSD17 enzyme able 
to support testosterone production in the mouse fetal tes-
tis. Recently, Hsd17b1 expression was localized to Sertoli 
cells in mice in fetal life.29 Ablation of this enzyme leads 
to disruption of the seminiferous epithelium and abnormal 
spermatozoa in adulthood, linking it to a role in the es-
tablishment of normal male fertility.29 As Hsd17b1 is able 
to convert androstenedione to testosterone this raises the 
possibility that HSD17B1 is responsible for basal andro-
gen production in fetal life, though as it is not expressed in 
the adult testis, is unable to explain the normal testosterone 
concentrations observed in the Hsd17b3−/− adult males.
Phylogenetic analysis of the hydroxysteroid family in 
human highlights the clustering of HSD17B3 and HSD7B12 
as well as HSD17B1 and HSD17B7.30 While the majority of 
the HSD17Bs share ~20% of amino acid sequence homology, 
F I G U R E  5  HSD17B3 acts as a rate-limiting step in testicular testosterone production. A, Immunolocalization of HSD17B3 following the 
intra-rete injection of control lentiviral particles (+lv GFP) and Hsd17b3 lentiviral particles (+lv Hsd17b3 (bar: 100 µm). Intratesticular hormones 
following intra-rete injection of control lentiviral particles (+lv GFP) and Hsd17b3 lentiviral particles (+lv Hsd17b3) that directs Hsd17b3 
expression into Sertoli cells (B) progesterone, 17-OH-progesterone, androstenedione, and testosterone in adult (d80) Hsd17b3−/− and controls 
littermates (n = 10 controls and n = 11 Hsd17b3−/− two-way ANOVA, *P < .05, ** P < .01, ***P < .001) (C) Circulating LH levels (from 
tail vein) reduce following the reintroduction of HSD17b3 (n = 4-7 controls and n = 6 Hsd17b3−/−, two-way ANOVA, *P < .05, ** P < .01, 
***P < .001). Controls correspond to Hsd17b3+/+ males pooled with Hsd17b3+/− males
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HSD17B3 and HSD17B12 share 40% of similarity,31 sup-
porting their overlapping activities. Further aligning to this, 
while ablation of Hsd17b12 function is embryonic-lethal in 
mice, heterozygous Hsd17b12 males display reduced levels 
of androgens.32,33 Our data also highlight Hsd17b12 as a pos-
sible candidate for basal testosterone production in the fetal 
and/or adult testis, as it is expressed in the testis through-
out life, and transcript levels are significantly increased in 
Hsd17b3−/− adult males. HSD7B12 in humans is present in 
Leydig cells and Sertoli cells34 and in “Human protein atlas” 
(www.prote inatl as.org)35 and has been identified in the pro-
teome of whole adult mouse testis26,36 and our own immuno-
histochemical analysis localizes HSD17B12 to Leydig cells 
and faintly in the germ cells in control and Hsd17b3−/− testes. 
However, while Hsd17b12 is able to convert androstenedione 
to testosterone in mice,37 its steroidogenic activity is largely 
restricted to estrone reduction to estradiol in humans, with 
low levels of androstenedione reduction.25,31 Overall, such 
species differences could explain why we observe normal 
masculinization of Hsd17b3−/− mice; while reproductive 
tissues are impacted in humans lacking HSD7B3. Whether 
this is the case, or indeed whether this explains the apparent 
dispensability of Hsd17b3 for basal testosterone production 
requires further investigation. A further explanation could be 
that, in humans, masculinization requires that both canonical 
and alternative (backdoor) androgen pathways are intact and 
the alternative pathway may also be dependent on a functional 
HSD17B3.38,39 This alternative pathway does not appear to 
be of importance in fetal masculinization in the mouse.40
HSD17B3 is a key enzyme in the biosynthesis of testos-
terone and models where the androgen signaling pathway 
is impacted, (eg, Tfm mice which lack Leydig cell-spe-
cific androgen receptor) have highlighted the importance 
of androgens for Leydig cell development.41,42 While the 
number of Leydig cells in adult is normal, Leydig cell 
function is perturbed. Androgen production from puberty 
is under the regulation of the hypothalamic-pituitary-go-
nad axis and stimulation of LH induces the upregulation of 
its receptor and other crucial steroidogenic markers.21 This 
upregulation can be seen in Hsd17b3−/− males with signifi-
cantly higher transcript levels of Lhcgr, StAR, Cyp11a1, 
and Cyp17a1. Increased LH and steroid levels (circulating 
and intratesticular) and the unresponsiveness to further 
hCG stimulation in the Hsd17b3−/− males is an indicator 
of possible compensated Leydig cell failure.22 The matu-
rity stage of the Leydig cells has been shown to impact 
the responsiveness of the cell to stimulation. However, the 
increase of both circulating LH and testosterone would 
suggest the absence of proper feedback regulation in the 
hypothalamo-pituitary-gonad axis. Literature shows that 
the programming actions of testosterone on the brain can 
be mediated by androgenic or estrogen action due to aro-
matization of testosterone. A sex-dependent regulation has 
also been suggested wherein androgens in males tend to 
inhibit the fetal neonatal gonadotrophin releasing hormone 
(GnRH) input compared to females and that daily treatment 
with GnRH agonist can impact the normal developmental 
changes in Leydig cell function.43-45 Kisspeptin signaling 
is a component of the neuroendocrine regulation of the re-
productive system and a role for kisspeptin in mediating 
the negative feedback effects of gonadal steroids on GnRH 
secretion in both the male and female via the estrogen and 
androgen receptor has been described.46,47 We speculate 
that in our Hsd17b3−/− model, the action of the high cir-
culating androgens, regardless of aromatization, impact the 
kisspeptin neurons and GnRH secretion consequently al-
tering the negative feedback, however, this requires further 
investigation.
While this data show that HSD17B3 is not strictly neces-
sary for testosterone production or fertility in the mouse, the 
enzyme is necessary for optimal testosterone production above 
basal levels. In fetal life, the conversion of androstenedione, 
F I G U R E  6  Expression of potential androgen converting AKR enzymes. Comparative testicular expression of (A) Hsd17b12 transcript in adult 
(d80) (n = 14 controls and n = 8 Hsd17b3−/−, t-test *P < .05), B, HSD17B12 protein localizes to Leydig cells, with evidence of lower expression 
in germ cells in both Hsd17b3+/+ (controls) and Hsd17b3−/− adult testis (bar: 100 µm). (−) ctrl stands for no primary control and IgG ctrl for IgG 
control
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produced by fetal Leydig cells, to testosterone is undertaken 
by Sertoli cells.3,42 In adulthood, in contrast, Leydig cells 
carry out the full canonical testosterone biosynthetic path-
way while Sertoli cells act to maintain Leydig cell viability 
and function.3,4,15,48 The reintroduction of Hsd17b3 in Sertoli 
cells in Hsd17b3−/− males was able to partially rescue the 
endocrine defect in Hsd17b3−/− males, indicating that the so-
matic cells of the adult testis can act cooperatively to produce 
testosterone.
In conclusion, this study expands our knowledge of testos-
terone production in the mouse which has implication for our 
wider understanding of masculinization and male fertility. In 
addition, the ability to re-express Hsd17b3 in Sertoli cells 
and manipulate this cell type to produce testosterone suggests 
that Sertoli cells could be engineered to produce androgens 
and could form the basis of future therapy to combat the nat-
ural decline in androgens during aging.
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